This $401,242.00 Project Grant award from the National Institute of General Medical Sciences (NIGMS), under its Biomedical Research and Research Training program (CFDA 93.859), will support research to improve drug development processes. The principal investigator plans to utilize innovative ATP-allosteric bivalent inhibitors (AABIs) targeting protein kinases to: 1) Selectively target the inactive state of kinases to rapidly identify promising new drug targets, 2) Elucidate the structural and functional factors influencing the activity of linked compounds for fragment-based drug design and PROTAC degraders, and 3) Analyze the causes of variability in covalent inhibitor activity assays to inform drug optimization. These interconnected research projects aim to fill gaps in knowledge and pave the way for accelerated development of new therapies. The award runs from August 1, 2024 to May 31, 2029 and is being administered by the Research Foundation for the State University of New York.
Generated 3/4/25, 8:34 AM